48 results about "Tumour volume" patented technology

The application relates to the technical field of biological medicine, and discloses a micropeptide miPEP060 coded by a LINC00060 gene and application thereof; the application provides the following application of LINC00060 and the micropeptide miPEP060 coded thereby: preparing a product for predicting tumor chemotherapy efficacy, preparing a product for predicting tumor prognosis; preparing a tumor treatment product, preparing a product for enhancing tumor chemotherapy efficacy, preparing a product for overcoming tumor chemotherapy drug resistance, preparing a product for inhibiting PARP1 enzyme activity or PARylation modification, and preparing a product for inhibiting replication stress response and replication fork stability; the LINC00060 and the micropeptide miPEP060 coded thereby provided by the application can significantly enhance the chemotherapy killing effect of tumor cells or tumor tissues and reduce tumor volume.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising interferon gamma.

The name of the invention is compositions and methods for enhancing cancer radiotherapy. A nutritional supplement comprising fish oil and selenium has been determined to enhance radiotherapy of tumors in a synergistic manner. The co-therapy of such supplements and radiotherapy results in a significantly improved reduction in tumor volume in animal models and reduces the common side effects, such as weight loss, inflammation and gastrointestinal tract damage, relative to radiotherapy alone. It has also been found that this co-therapy can reduce the incidence of metastasis from a primary implant site and modulate the expression of genes associated with apoptosis in tumor cells. Formulations of such supplements with good tolerance and palatability are also provided.

The present disclosure relates to representation learning for treatment response prediction of risk organs and total tumor volume. For predicting the response of radiation therapy, radiomics is used for unsupervised machine training of an encoder-decoder network to predict based on input of image data, such as computed tomography image data, and from segmentation. Then, the trained encoder is used to generate latent representations to be used as input to different classifiers or regressors for predicting the treatment response, such as one classifier for predicting the response for a risk organ and another classifier for predicting another type of response for a risk organ or predicting the response for a tumor.

The invention relates to a predictive gene expression signature of response to antiangiogenic drugs, such as axitinib, in gastro-enteric-pancreatic and pulmonary neuroendocrine tumours. The signature is formed by the gene expression of three genes (SPP1, ATXN7 and REXO1L2P), which is converted by means of a bioinformation packet into a unique score that can predict which patients will benefit from treatment with the drug, this benefit being understood as longer survival without progression and larger tumour volume reductions in response to treatment.

Potential prognostic biomarkers for CD26-targeted therapy were identified based on phase I study data of a humanized anti-CD26 monoclonal antibody YS110 against CD26-expressing tumors. Using boxplot analysis, scatter plot analysis, Pearson's product-moment correlation / Spearman's rank-difference correlation, bar graph analysis, and receiver operating characteristic (ROC), a correlation between soluble CD26 titer variation and tumor volume variation by YS110 administration, RECIST criteria evaluation, and progression-free survival (PFS) were examined. Further, mechanism of serum soluble CD26 titer variation was confirmed by in vitro experiments. As a result, serum soluble CD26 / DPP4 titer variation at an early stage of YS110 treatment was found for the first time as a predictive biomarker to evaluate a therapeutic effect.

The invention discloses a closed tumor-free drainage apparatus for abdominal tumors, which relates to the field of medical instruments, and comprises a protective sleeve, a sealing mechanism, a limiting mechanism and a sealing mechanism, the protective sleeve is used for protecting when drainage mass cyst fluid is used for reducing the volume of the tumors aiming at the huge tumors (cystic solid / cystic) of the pelvic and abdominal cavities, and the sealing mechanism is used for sealing and attaching the protective sleeve and the tumor cyst wall. The limiting device is arranged at the top of the protective sleeve and used for limiting and controlling the size of an opening in the top of the protective sleeve and sealing the whole protective sleeve after drainage operation is finished to prevent cystic fluid from flowing out to the pelvic cavity; by means of the protective sleeve, a drainage tube can penetrate through the interior of the protective sleeve to drain cyst fluid in the wrapping block in a clinical operation of excising a huge tumor of the pelvic cavity, the protective sleeve can protect drainage of the drainage tube and prevent the cyst fluid from flowing into the pelvic cavity and generating a spreading risk, and after the cyst fluid of the wrapping block is drained, the size of the wrapping block can be reduced, and the size of the wrapping block is reduced. In this way, excision operation can be conveniently conducted on the masses, and the length of an abdominal incision can be shortened during laparotomy.

The present application discloses an application of RAB32 in the preparation of products for the diagnosis, treatment and prognosis of non-small cell lung cancer. In the present application, RAB32, a member of the small GTPase RAB family, is significantly more highly expressed in non-small cell lung cancer tissues and cell lines than in adjacent cancer tissues and normal cells, and is associated with a poor prognosis. In vitro experiments show that knocking down the highly expressed RAB32 gene in tumor cells can significantly inhibit the proliferation of lung adenocarcinoma cells. In an in vivo tumor-bearing mouse model, knocking down the RAB32 gene significantly reduced the tumor volume and inhibited its growth in the knockdown group, while also inhibiting the lymph node metastasis ability of lung adenocarcinoma cells. Therefore, the RAB32 gene can be used in the preparation of products for the diagnosis, treatment and prognosis of non-small cell lung cancer.

The invention relates to the field of tumor volume detection, and discloses a TOF technology-based tumor volume detection device for a gastrointestinal endoscope, the TOF technology-based tumor volume detection device comprises a gastrointestinal endoscope body, a detection head is mounted on one side of the gastrointestinal endoscope body, and a CCD cable, a forceps tube, an air supply tube and a water supply tube are sequentially mounted in the detection head; illumination light sources are symmetrically mounted in the middle of the detection head, a mounting block is fixedly connected to one side of the detection head, an adjusting and limiting structure is fixedly mounted on one side of the mounting block, and a scraping plate is arranged on one side of the adjusting and limiting structure. The scraping plate can be driven by the adjusting limiting structure to clean one side of the detection head, the cleaning efficiency is enhanced through the water spraying structure when the scraping plate is cleaned, the position of the TOF sensor on the mounting block can be adjusted according to requirements by utilizing the adjusting limiting structure, the size of a tumor block is measured by utilizing the TOF sensor, and the detection efficiency is improved. And real volume data of the tumor in the body is obtained.

The invention discloses a personalized preoperative risk assessment method for a spinal tumor resection operation, and the method comprises the steps: carrying out the standardization processing of features extracted from the case data of a patient and the corresponding operation plan data, and obtaining the processed features; the method comprises the following steps: preprocessing medical image data to obtain preprocessed data, performing tumor segmentation on the data through a three-dimensional attention U-Net network to obtain a tumor voxel-level probability graph, and calculating a tumor volume; obtaining the type of the tumor through the preprocessed data, the double-flow deep network and the type discrimination network; respectively carrying out standardization processing on the type, the tumor volume, the extracted wettability score and the tumor position grade to form a third feature; obtaining basic weights of the processed features and the third features from a historical database, and then dynamically adjusting the basic weights to obtain a target weight; and performing weighted summation on the target weight, the processed feature and the third feature to obtain a risk score, and matching the risk score with a preset risk score to obtain a preoperative risk assessment level.

The invention discloses a high-throughput lung cancer gene screening system and method based on CRISPR (clustered regularly interspaced short palindromic repeats), and relates to the technical field of gene screening. According to the method, full-lung three-dimensional visualization and automatic classification and identification of the lung tissue tumor can be realized without tissue slicing, and the mass center of the tumor, the structural characteristics and the interaction relationship with the host tissue are extracted in combination with a space coordinate system. On the basis, the system constructs a multi-parameter risk evaluation index system, proposes a tumor comprehensive evaluation score S based on the shortest distance d between the tumor and the lung lobe surface in combination with the tumor volume V and the ratio R of tumor cells to host cells, and introduces a dual threshold judgment mechanism to perform risk grading on different tumor types. Compared with traditional two-dimensional slice morphology or sequencing enrichment scoring, the quantitative evaluation method can accurately identify structure invasion period and in-situ stable tumors.

This invention discloses a tumor volume detection device for gastrointestinal endoscopy based on Time-of-Flight (TOF) technology, specifically in the field of tumor volume detection technology. It includes a gastrointestinal endoscope body. The front end of the endoscope body includes a CCD cable, two illumination sources, an air supply pipe, a water supply pipe, and a forceps pipe. The air supply pipe and water supply pipe are located between the two illumination sources. The CCD cable is located at the top of the forceps pipe. A mounting plate is fitted onto the outer side of the front end of the endoscope body. This invention uses an electric telescopic rod to retract a toothed plate, which, through meshing with gears, drives a drive shaft and a support plate to rotate, rotating the TOF sensor between the two illumination sources. The tumor is then irradiated by the illumination sources. During irradiation, the TOF sensor measures the size of the tumor by calculating the time difference between the time of light emission and the time of light reflection. The overall structure facilitates the measurement of tumor size.

The present application provides a prognostic marker for neoadjuvant immunotherapy and chemotherapy of lung cancer, which is the change rate of tumor volume before and after early treatment of lung cancer. In the early treatment of lung cancer, by combining the method of artificial intelligence, the volume change of tumor lesion is used as the feature of treatment effect, and it is observed from the Kaplan-Meier curve that the change amount of tumor volume has a more obvious difference between the two groups of patients.

The present invention relates to a fusion protein comprising: an interleukin-21 (IL-21) polypeptide, and an antibody or antigen binding fragment that binds at least one of CD8a, CD8aa or CD8aß having

The present disclosure provides microbial consortia that are useful as therapeutics, for example, for treating cancer and / or reducing tumor volume or tumor growth in patients.

A composition of microparticles includes a non-radioactive and a radioactive isotope, and an injection vehicle, for use in the intratumoral treatment of cancer, by combined antitumoral effect of radioactivity and intratumoral microparticle deposition. The antitumoral effect provided by the cytotoxicity of radioactivity is enhanced by a modulation of the tumoral immune response induced by microparticle deposition inside the tumor, thereby decreasing the dose of radioactivity required to treat solid tumors. A method of treating solid tumors using a sub-optimal tumor-volume coverage dose of radioactivity combined with intratumoral microparticle deposition as a mean of tumor control is also disclosed.

The invention provides a tumor magnetic sensitive signal extraction method and device based on an ESWAN sequence, equipment and a medium. The method comprises the following steps: acquiring a tumor phase diagram of a target part; inputting the tumor phase diagram into a preset medical image processing model, and sketching a suspected focus area in the tumor phase diagram to generate a focus sketching area; generating a three-dimensional region of interest according to the focus sketching region; based on the three-dimensional region of interest, the ratio of the magnetically sensitive signals within the volume of the tumor is obtained, and evaluation of the overall structure and heterogeneity of the tumor can be provided.

The present disclosure provides microbial consortia that are useful as therapeutics, for example, for treating cancer and / or reducing tumor volume or tumor growth in patients.

The invention relates to a predictive gene expression signature of response to antiangiogenic drugs, such as axitinib, in gastro-enteric-pancreatic and pulmonary neuroendocrine tumours. The signature is formed by the gene expression of three genes (SPP1, ATXN7 and REXO1L2P), which is converted by means of a bioinformation packet into a unique score that can predict which patients will benefit from treatment with the drug, this benefit being understood as longer survival without progression and larger tumour volume reductions in response to treatment.

The application discloses a non-small cell lung cancer fractionated radiotherapy progress prediction method based on a mathematical mechanism model, which is based on in-depth research on tumor proliferation mechanism and radiotherapy killing effect, and simultaneously carries out segmented integral analysis on the fractionated radiotherapy process, constructs a mathematical mechanism model considering dynamic growth change of tumor volume in the fractionated radiotherapy process, and realizes non-small cell lung cancer fractionated radiotherapy progress prediction by using the mathematical mechanism model. The application can use low-cost python software to realize one-key personalized simulation of NSCLC fractionated radiotherapy progress, provides a new visual angle of numerical simulation for doctors, accurately predicts the volume change of the tumor of a patient after fractionated radiotherapy, and provides a recommended scheme, potential opportunity, reference dose and interval frequency and the like for intervention and intervention of radiotherapy planning.

The invention discloses a GPC3 targeting chimeric antigen receptor gamma delta T cell and an application thereof in treatment of hepatocellular carcinoma. The CAR-gamma delta T cell has a third-generation CAR structure and has high targeting accuracy and killing efficiency, the in-vitro killing rate of GPC3 positive hepatoma carcinoma cells (HepG2 / Hep3B) is larger than 90% (the efficiency-target ratio is 10: 1) and is obviously improved compared with that of common gamma delta T cells, the tumor size is obviously reduced in a PDX mouse model, and the excellent treatment effect of the CAR-gamma delta T cell is proved.

This disclosure relates to modulating IL-2 expression / activity to prevent or treat diseases (cancer, autoimmune diseases, inflammatory diseases, or infections). Compounds of formula (I), as well as compositions comprising their conjugates, complexes, and pharmaceutical compositions, as well as methods of using them to modulate (e.g., increase) IL-2 expression / activity to achieve desired results (e.g., reduction in cancer cell viability, growth, proliferation, or metastasis; reduction in tumor volume; increase in survival; increase or decrease in immune cell proliferation or activation; increase or decrease in cytokine production; decrease in autoimmunity; decrease in inflammation, etc.). Related pharmaceuticals, kits, and methods of delivering such compositions are described. Compounds of formula (I) and methods for developing or manufacturing their pharmaceutical compositions are provided. Diagnostic and test methods for detecting levels of IL-2 expression / activity, as well as compositions constituting diagnostic or test kits, are further described. JPEG2026513223000025.jpg3642

The utility model discloses a device suitable for measuring the volume of a tumor, and relates to the technical field of medical instruments, in particular to the device suitable for measuring the volume of the tumor, which comprises a measuring cylinder and a placing cylinder, and a communicating pipe is fixedly connected on the side wall of the middle part of the measuring cylinder; when the volume of an in-vitro tumor is measured, clear water is poured into a placing barrel, the water submerges a clamping part, the liquid level in the placing barrel is flush with an upper end opening of a communicating pipe, a circular plate is pushed by an air cylinder to ascend and move out of the liquid level, the tumor is placed on the circular plate, the air cylinder descends and drives all limiting assemblies to clamp the tumor, and the clamping part drives the tumor to be submerged in the water; the volume of the clamping part in the water is not changed, after the tumor is submerged in the water, the liquid level in the placing cylinder is raised, and discharged water caused by the fact that the tumor is submerged in the water flows into the measuring cylinder through the communicating pipe, so that the volume of the tumor is obtained by measuring the volume of the discharged water, and the volume of the tumor is accurately measured.

The application provides application of VPS53 in intervention target of thyroid cancer caused by long-term low-dose ionizing radiation, and belongs to the technical field of biological medicine.The application takes VPS53 as the intervention target of thyroid cancer caused by long-term low-dose ionizing radiation, finds that the copy number of VPS53 gene increases after long-term low-dose irradiation, and the expression level of VPS53 increases.In the thyroid cancer cell line with high expression of VPS53, the expression of VPS53 is knocked down, the proliferation, migration and invasion ability is weakened, the tumor volume is smaller, and the tumor grows more slowly;in the thyroid cancer cell line with low expression of VPS53, the expression of VPS53 is overexpressed, the proliferation, invasion and migration ability is enhanced, the tumor volume is larger, and the tumor grows faster.The application proves that knocking down VPS53 is a candidate intervention target of the occurrence and development of thyroid cancer caused by long-term low-dose ionizing radiation.

A pharmaceutical composition, comprising panobinostat and tazemetostat. Combination of tazemetostat which is an EZH2 inhibitor with panobinostat, pembrolizumab and ipilimumab is clinically used for treating patients suffering from later-stage diffuse midline glioma, H3K27-altered, accompanied with leptomeningeal / pia mater spinalis spread, and patients suffering from primary, relapsing and progressing diffuse midline glioma, H3K27-altered. The pharmaceutical composition has remarkable curative effects, can obviously inhibit tumor growth, reduce the tumor volume, improve the life quality for patients, and prolong the survival time of patients.

The invention discloses a non-small cell lung cancer fractional radiotherapy progress prediction method based on a mathematical mechanism model, and the method is based on a deeply researched tumor proliferation mechanism and radiotherapy killing effect, and carries out the segmented integral analysis of a fractional radiotherapy process. A mathematical mechanism model considering the dynamic growth change of the tumor volume in the fractional radiotherapy process is constructed, and the progress prediction of the fractional radiotherapy of the non-small cell lung cancer is realized by using the mathematical mechanism model. According to the method, one-key personalized simulation of the progress of NSCLC fractional radiotherapy can be realized by using low-cost python software, a new visual angle of numerical simulation is provided for doctors, the volume change of tumor of a patient after fractional radiotherapy is accurately predicted, and a recommended scheme, potential opportunity, reference dose, interval frequency and the like are provided for intervention of radiotherapy planning.

Compositions, kits, combinatorial treatments, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, along with increasing median survival of a subject with cancer, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising at least one angiotensin-converting enzyme (ACE) inhibitor.

The invention discloses a culture medium capable of remarkably improving in-vitro amplification efficiency and antitumor activity of NK (Natural Killer) cells. The culture medium comprises (1) a basic culture medium, namely an RPMI 1640 culture medium containing 10% of human AB serum, 1% of GlutaMAX and 0.1% of beta-mercaptoethanol; (2) fusion polypeptide: the final concentration is 150ng / mL, and the IL-15 mutant is connected with the NKG2D ligand ULBP2, so that dual-channel synergistic activation of IL-15R and NKG2D is realized; and (3) an anti-PD-1 antibody with a final concentration of 30 [mu] g / mL, wherein the anti-PD-1 antibody blocks a PD-1 / PD-L1 inhibition signal. Experiments show that after the culture medium is used for culturing for 7 days, the NK cell amplification multiple can reach 39.8 times, the CD69 activation proportion is increased to 83.6%, and the apoptosis rate is reduced to 6.5%. The killing rate of PD-L1 + tumor cells in vitro is increased to 64.7%, the tumor volume inhibition rate in a tumor-bearing mouse model reaches 66.4%, and the median lifetime is prolonged to gt; and 60 days. According to the invention, the existing NK cell amplification and activity limitation is broken through through a multi-channel synergistic effect, and an efficient solution is provided for solid tumor immunotherapy.

The invention provides application of a KRAS inhibitor combined with glucocorticoid in preparation of a medicine for treating cancers, and belongs to the technical field of biological medicines. The invention provides a combined application of a KRAS inhibitor and glucocorticoid in preparation of a medicine for treating cancers. Compared with the single use of the KRAS inhibitor or prednisolone, the combined use of the KRAS inhibitor and prednisolone can more effectively inhibit the proliferation and survival of KRAS G12C mutated NSCLC cells and slow down the growth of tumor volume. In addition, prednisolone can relieve the acquired drug resistance problem of KRASi by blocking generation of TNF and I-type IFN induced by a KRAS inhibitor, and prednisolone and prednisolone have a synergistic anti-tumor effect. The two can be directly combined for medication, can also be prepared into a combined agent for treating cancers, and has a good clinical transformation prospect.